- N Engl J Med 2022; 386:2531-2532
Adult influenza vaccination rates decreased in states with below-average Covid-19 vaccination rates, a finding that raises the possibility that mistrust in Covid-19 vaccines adversely affected influenza vaccination.
- N Engl J Med 2022; 386:1638-1645
Development and public acceptance of vaccines are crucial for disease control. This review covers the process of evaluating vaccines for safety and efficacy, authorization pathways, and factors that advisory bodies consider when establishing vaccine recommendations.
- N Engl J Med 2022; 386:1087-1088
In this report, a young man with severe pneumonia is found to be infected with an H10N3 influenza A virus. He recovered with aggressive supportive care.
- N Engl J Med 2021; 385:1825-1827
Given the parade of SARS-CoV-2 variants, their increasing transmissibility, and concern about antigenic changes affecting vaccine protection, we need long-term plans for dealing with this virus. Pandemic and seasonal influenza may provide appropriate models.
- N Engl J Med 2021; 385:1485-1495
There is a need for improved production of the influenza vaccine, including a shorter time from antigen identification to vaccine availability and minimization of the development of egg-adapted mutations. In a trial involving healthy children, a cell-culture–derived quadrivalent influenza vaccine had efficacy against the circulating influenza serotypes.
- N Engl J Med 2021; 385:1159-1161
This Graphic Perspective explores the fraught history of masking as a preventive intervention in public health crises. Masks themselves have evolved, but the existence of mask slackers and questions about balancing individual rights with the public good are not new.
- N Engl J Med 2020; 383:1813-1826
In this randomized, double-blind trial in 1062 adults hospitalized with Covid-19, remdesivir was superior to placebo in shortening the time to recovery (10 days, vs. 15 days with placebo). The estimates of mortality by day 29 were 11.4% with remdesivir and 15.2% with placebo. The benefit of remdesivir was most...
- N Engl J Med 2020; 383:1886-1887
In May 2020, Beigel et al. provided in the Journal the first report of an effective treatment for Covid-19, resulting from a rigorously designed and conducted clinical trial.1 It is remarkable that a randomized, placebo-controlled trial of a potential antiviral treatment for a disease whose pathogenesis...
- N Engl J Med 2020; 383:389-390
In the United States, antiviral treatment of influenza is recommended as soon as possible in hospitalized patients and in outpatients who are at increased risk for influenza complications or have progressive disease, and it can be considered in non–high-risk patients presenting within 2 days after the onset of illness (early...
- N Engl J Med 2020; 383:309-320
In a randomized, double-blind trial that treated household contacts of patients with influenza with a single dose of baloxavir or placebo, participants taking baloxavir had a lower risk of influenza (1.9%) than placebo controls (13.6%). Adverse events were similar in the two groups.
- N Engl J Med 2020; 383:184-185
Young children often have annual visits with pediatricians near the time of their birthdays. An analysis of insurance claims data showed that children 2 to 5 years old with birthdays in September through December were more likely to receive influenza vaccination and less likely to have influenza than those with...
- N Engl J Med 2020; 382:2005-2011
On February 28, 2020, public health officials in the Seattle area were informed of a Covid-19 infection at a long-term care facility. An investigation identified 167 infected persons associated with the facility, including residents, health care personnel, and visitors; more than a third of the 101 residents identified died.
- N Engl J Med 2020; 382:2012-2022
Clinicians and investigators report on the first 24 patients admitted to ICUs from nine Seattle area hospitals. Key aspects of the clinical presentation, treatment, and outcomes are described.
- N Engl J Med 2020; 382:1858-1859
Among 28 early confirmed cases of Covid-19 in South Korea, diagnosis was delayed in 11 patients because of subclinical symptoms and diverse initial manifestations. Covid-19 was diagnosed by surveillance testing in 3 patients who were asymptomatic.
- N Engl J Med 2020; 382:1851-1852
Lindsey Baden and Eric Rubin comment on the findings of an urgent randomized clinical trial of a possible treatment for Covid-19 in Wuhan, China. They note that whether the findings of such trials are positive or negative, they will be central to clinical care as the pandemic continues.
- N Engl J Med 2020; 382:1787-1799
Investigators in China report the results of an open-label, randomized clinical trial of lopinavir–ritonavir for the treatment of Covid-19 in 199 infected adult patients. The primary end point was the time to clinical improvement.
- N Engl J Med 2020; 382:1708-1720
In this study, researchers describe the clinical characteristics of coronavirus disease 2019 in a selected cohort of 1099 patients with laboratory-confirmed disease throughout mainland China during the first 2 months of the current outbreak.
- N Engl J Med 2020; 382:1663-1665
In this report, investigators in Wuhan, China, describe the spectrum of Covid-19 illness in children under the age of 16 years. Of 1391 children assessed and tested over a period of 4 weeks, 171 (12.3%) were confirmed to have SARS-CoV-2 infection.
- N Engl J Med 2020; 382:1370-1371
A retrospective analysis of routine surveillance data involving children hospitalized in central Wuhan, China, for acute lower respiratory infection in early January 2020 revealed six cases of Covid-19. The authors report clinical characteristics of the children and laboratory data.
- N Engl J Med 2020; 382:1268-1269
Fauci, Lane, and Redfield comment on the early clinical features and epidemiology of cases reported in Wuhan, China, along with current mortality data, noting that the outbreak is a stark reminder of the need for constant surveillance, prompt diagnosis, and robust research.